Suppr超能文献

肺移植——适应证、随访及长期结果

Lung Transplantation—Indications, Follow-Up Care and Long-Term Results.

作者信息

Michel Sebastian, Schneider Christian, Ius Fabio, Welte Tobias, Gottlieb Jens, Kneidinger Nikolaus

机构信息

Department of Cardiac Surgery, LMU Hospital Munich, and Munich Heart Alliance, German Center for Cardiovascular Research (DZHK), Munich, Germany; Comprehensive Pneumology Center Munich, German Center for Lung Research (DZL), Munich, Germany; Division for Thoracic Surgery, LMU Hospital Munich, Germany; Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Gemany; Biomedical Research in Endstage & Obstructive Lung Disease Hannover (BREATH),German Center for Lung Research (DZL), Hannover, Germany; Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Germany; Medical Clinic and Polyclinic V, Pneumology, LMU Hospital Munich, and Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Austria.

出版信息

Dtsch Arztebl Int. 2025 Jan 24;122(2):43-48. doi: 10.3238/arztebl.m2024.0232.

Abstract

BACKGROUND

Lung transplantation is the treatment of choice for end-stage nonmalignant lung disease. It has become a routine procedure through advances in donor lung preservation, extracorporeal membrane oxygenation, immunosuppression, intensive care medicine, and follow-up care.

METHODS

This review is based on publications about lung transplantation that were retrieved by a selective literature search, and on the procedures and experience of two large-volume lung transplantation centers.

RESULTS

The mean survival time after lung transplantation is six years, which is the shortest after the transplantation of any solid organ. Chronic graft dysfunction is present in 41% of patients at five years and is the main cause of death after lung transplantation, followed by infection and cancer.

CONCLUSION

Despite all the advances in lung transplantation, acute and-above all-chronic graft dysfunction still pose a major challenge for large-volume transplantation centers. Immunosuppression that is individually tailored to prevent both graft rejection and infection is important for these patients' longterm survival. Xenotransplantation and so-called lung bioengineering may become available in the future as alternatives to allotransplantation.

摘要

背景

肺移植是终末期非恶性肺部疾病的首选治疗方法。通过供肺保存、体外膜肺氧合、免疫抑制、重症医学及后续护理等方面的进展,肺移植已成为一种常规手术。

方法

本综述基于通过选择性文献检索获取的有关肺移植的出版物,以及两个大型肺移植中心的手术和经验。

结果

肺移植后的平均生存时间为6年,这是所有实体器官移植后最短的。41%的患者在5年后出现慢性移植物功能障碍,这是肺移植后死亡的主要原因,其次是感染和癌症。

结论

尽管肺移植取得了所有进展,但急性尤其是慢性移植物功能障碍仍然是大型移植中心面临的重大挑战。为预防移植物排斥和感染而进行个体化调整的免疫抑制对这些患者的长期生存至关重要。异种移植和所谓的肺生物工程未来可能成为同种异体移植的替代方法。

相似文献

本文引用的文献

1
Living-donor lobar lung transplantation.活体供肺叶移植。
J Heart Lung Transplant. 2024 Jan;43(1):162-168. doi: 10.1016/j.healun.2023.09.006. Epub 2023 Sep 11.
4
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.索他洛尔治疗肺动脉高压的3期试验
N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558. Epub 2023 Mar 6.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验